Preliminary Results

RNS Number : 4561H
Gooch & Housego PLC
01 December 2015
 

For immediate release

1 December 2015

 

Gooch & Housego PLC

PRELIMINARY RESULTS FOR THE YEAR ENDED 30 SEPTEMBER 2015

Gooch & Housego PLC ("Gooch & Housego", or "G&H", or the "Company", or the "Group"), the specialist manufacturer of optical components and systems, today announces its preliminary results for the year ended 30 September 2015.

 

Year ended 30 September

2015

2014

Change

Revenue (£m)

78.7

70.1

12.3%

Adjusted profit before tax (£m)*

12.9

11.5

12.2%

Adjusted basic earnings per share (pence)*

39.5

35.6

11.0%

Statutory profit before tax (£m)

10.1

7.9

27.8%

Basic earnings per share (pence)

30.9

22.5

37.3%

Total dividend per share (pence)

8.2

7.2

13.9%

Net cash (£m)

17.3

8.7

98.9%

*adjusted figures are stated after excluding the amortisation of acquired intangible assets, gain on bargain purchase and exceptional items being restructuring costs and impairment of goodwill.

Operating & Strategic Highlights

·      Strong performance from industrial laser and telecommunication products

·      Melbourne site closure completed and products transferred to other G&H sites

·      Performance improvement initiatives underway

·      Investment in R&D up 14.2%

Financial Highlights

·      Adjusted profit before tax up 12.2%

·      Strong cash performance delivering net cash of £17.3m at year end (2014: £8.7m)

·      Solid order book of £36.3m, up 11% from 30 September 2014

·      13.9% growth in full year dividend

Mark Webster, Chief Executive Officer, commented

"During 2015 Gooch & Housego has made good progress in executing on its strategic objectives, met management's expectations for revenue and profit growth and made a number of significant investments in line with our strategic vision for the business.

 

The near and long term benefits of these strategic initiatives, combined with a solid year end order book, mean the Board believes Gooch & Housego remains well positioned to deliver further progress in 2016 and beyond."

 

For further information please contact:

Gooch & Housego PLC

Mark Webster / Andrew Boteler

01460 256 440




Investec Bank plc  (Nomad & Broker)

Patrick Robb / David Anderson

020 7597 5970

Buchanan

Mark Court / Gabriella Clinkard

020 7466 5000


 

 

Expected Financial Calendar

Annual General Meeting

 

Final dividend for the year ended 30 September 2015 to shareholders on the register at close of business 18 December 2015.

Subject to approval by shareholders at the Annual General Meeting

 

Interim Results announced

 

Financial Year End

 

Preliminary announcement of results for the year ended

30 September 2016

24 February 2016

 

3 March 2016

 

 

 


June 2016

 

30 September 2016

 

December 2016

 

 



 

 

Chairman's Statement

I am pleased to report that your company performed well in 2015, achieving encouraging growth in revenues and profits. In parallel, significant management and operational changes were implemented to support the long-term development of the business.

 

The year was characterised by generally benign market conditions supplemented by high levels of demand for a number of key products for which Gooch & Housego is the market leader. Although this demand presented significant challenges in terms of manufacturing capacity, the sites responded well and were able to keep pace with customer requirements. While some softening in the Chinese microelectronics market has subsequently been experienced, demand from other sectors and geographies has been maintained, illustrating that the Company's strategy of diversification is proving to be effective in smoothing out the swings of these traditionally cyclical markets.

 

2015 saw further increases in investment in Research & Development (R&D) and Business Development, including several senior appointments, in support of the Company's other key strategic objective of delivering growth and margin improvement by moving up the value chain. Several of the initiatives commenced in 2015 are already showing promise, and have the potential to generate revenue in the coming year.

 

Enhancing the quality, efficiency and capacity of the Company's manufacturing facilities, while reducing operational costs and complexity, has been a long term objective of the board. During 2015 the Melbourne site was closed, following the successful transfer of business to Ilminster and Palo Alto, work was started on major improvements to the Cleveland facility, and work is well advanced with the relocation of Palo Alto operations to a new, larger facility in nearby Fremont.  

 

In January this year I was pleased to hand over the role of CEO to Mark Webster and take over the position of Chairman on the retirement of Julian Blogh. I would like to record my thanks to Julian for his support and guidance over the years. In November 2014, Alex Warnock joined the Board as Chief Operating Officer. Mark and Alex bring additional skills and experience to Gooch & Housego and, together with the other executives, constitute a leadership team that can take the Company to the next level. I am pleased to report that the transition went smoothly, with no loss of continuity. I would also like to welcome Brian Phillipson, who joined as a non-executive director on 1 September 2015. Brian brings a wealth of Aerospace & Defence industry experience to the Board.

 

The new executive team has already made considerable progress in delivering a more efficient, effective and focussed Gooch & Housego. Initiatives to instil a culture of continuous improvement are already well advanced. Specialist teams operating across all sites have been established to ensure operational excellence in critical business functions. R&D has been refocused on fewer key projects, and experienced project managers hired to deliver them.

 

In summary, 2015 has been a positive year of growth and change for Gooch & Housego. With a strong balance sheet, good cash flow and enhanced facilities, processes and systems, the Company is well positioned to exploit exciting growth opportunities in photonics. I would like to thank my fellow directors and employees of Gooch & Housego for making 2015 another successful year for the Company.

 

Gareth Jones

Chairman


 

Chief Executive Officer's Statement

Overview of 2015

 

Gooch & Housego ("G&H") made good progress towards its aim of driving higher organic growth from its portfolio of world leading products and technologies. Revenue growth of 12% (8% on a constant currency basis) and the consequent contribution has enabled us to meet our profit targets and fund further investment in line with our stated strategic goals during 2015.

 

Our strategy is based around a continued commitment to the twin pillars of diversification and moving up the value chain. Further progress has been made against these goals resulting in a more balanced and vertically integrated business that is more robust and means we are less exposed to the cyclical nature of some of our core markets.

 

This was evident during 2015 where the use of lasers in microelectronic manufacturing, modulator systems for telecommunications and amplifiers for undersea cabling were the primary growth drivers for the first half of the year. In the second half of the year there was some softening of demand for microelectronic manufacturing in China, but this was largely offset by stronger demand elsewhere in the business, most notably high reliability fibre couplers used in amplifiers for undersea cabling.

 

The Systems Technology Group (STG), based in Torquay, which is dedicated to helping G&H move up the value chain, has continued to expand and now has 24 engineers and scientists. They bring a wide range of skills in areas such as electronic, software and mechanical engineering, which are necessary to design, engineer and deliver a complete sub-system or system to our customers.

 

The STG has been successful at securing grant funding for most of its projects, in particular for Space Satellite Communications ("SatCom") where we have funding from the European Space Agency, UK Space Agency and European Union. Our goal is to establish a medium term leadership position in the new and exciting area of space photonics. We are expecting to generate SatCom commercial income in 2016, which is far earlier than originally anticipated.

 

The new management team has made good progress with G&H's performance improvement programme, which is focused on operational excellence, business development and research and development (R&D). Our aim is to move to a more unified global business, where the skills, expertise and technology across our sites are better leveraged throughout G&H and our customers are presented with a more complete and professional offering.

 

The accompanying organisational changes and upgrading of the broader group of senior managers' skills and competencies has taken a significant step forward this year and is part of an ongoing process carrying on into 2016 and beyond.

 

During 2015:

 

·      The operations group has established a number of globally focused teams representing the key manufacturing disciplines. Lean Manufacturing principles are now being introduced to all of our sites.

 

·      Experienced Aerospace & Defence ("A&D") business development executives have been hired on both sides of the Atlantic. Two of our current key R&D projects would not have been possible without the expertise and contacts these executives brought with them. The next stage will be the hiring of experienced Life Sciences business development executives.

 

·      A more targeted R&D approach has been adopted, where fewer but better resourced projects are selected on the basis of the highest return on investment. The projects are now run by a new global R&D group, whose aim is to leverage our skills and technology across the whole company.

 

G&H's cash position has significantly strengthened over 2015 and, when taken in conjunction with our debt financing facilities, puts us in a strong position to make strategic acquisitions as and when the right opportunities become available.

 

Markets and Applications - Industrial

The Industrial sector represents 59% of G&H's revenue and is composed of a diverse range of industrial applications aligned to our world class photonic technologies, which include microelectonic manufacturing, semiconductor manufacturing and test, remote sensing, metrology and telecommunications. Revenue growth of £6.2 million, which is 15.7% higher than the previous year is reflective of positive trends across most of the sector.

 

The ongoing shift towards the use of fibre optics in general, and fibre lasers in particular, is something we see continuing into the foreseeable future. Fibre lasers are being used in an ever-widening number of applications and are proving to be more versatile than conventional solid-state lasers.

 

As the world leader in acousto-optic products for industrial lasers G&H anticipated this trend and is well positioned to take advantage. Acousto-optic components for fibre lasers, such as the 'Fibre Q' already represent a greater share of our business than the traditional 'Q- Switches' for water or conduction cooled solid state lasers.  Further investment in new products and cost reduction initiatives should enable us to retain a market leading position in this area.

 

The semiconductor manufacturing and test market showed particularly strong growth in 2015. The need for laser technology to enhance miniaturisation and speed in this fast moving sector means we anticipate that this will be a good growth driver for G&H over the medium term.

 

Free space and fibre lasers are being used increasingly in sensor applications and G&H has strengthened its position in this area over the last year.

 

The need to meet government, industry and consumer demand for more data capacity has driven an especially strong telecommunications performance over the last year. G&H products for modulation systems and high reliability fibre optics for undersea cabling have performed particularly well.  We expect this trend for more data capacity to continue into 2016.

 

Markets and Applications - Aerospace & Defence

 

A&D represented 25% of G&H's revenue during 2015, which was £1.0 million higher than the previous year. This reflects a sector that has recovered some of its confidence, is now placing new orders and initiating new engineering contracts and also the investment G&H has made in people and new products in this market.

 

Despite the revenue growth there was a year on year drop in adjusted profit due to the loss of a 'one time' contract and price pressure on a long standing contract at our Orlando and Moorpark sites respectively, coupled with the incremental investment in A&D experts. However, our new products, combined with exciting opportunities in space photonics and the application of existing capabilities to surveillance, displays and secure communications, mean we continue to believe this is a market with good growth prospects for Gooch & Housego.

 

Product quality, reliability and performance are paramount in this sector and that plays to G&H's strengths, along with our commitment to provide value. We have strong, well established positions in target designation and range finding, ring laser and fibre optic gyroscope navigational systems, infrared and RF countermeasures and space photonics, with the major A&D companies in both Europe and the USA.

 

Our fibre and infrared optic capabilities reflect the technological 'direction of travel' for this sector. Some of our current A&D customers prefer us to provide sub-systems and systems rather than just high quality components. We believe more of our major A&D customers will follow in their footsteps, as we establish further capability and capacity. The continued expansion of the STG and the hiring of experienced A&D executives should provide us with the critical mass to support further sub-system and system growth in this important sector.

 

The exciting potential of our space photonics business has been documented in the Overview section. 

 

 

Markets and Applications - Life Sciences

 

Life Sciences represented 11% of G&H's revenue during 2015, which was £1.7 million higher than the previous year.  The principal applications are in optical coherence tomography (OCT), laser surgery and microscopy. OCT is widely used in ophthalmology and G&H has developed a strong position with the main participants in this market. The potential for OCT medical diagnostic techniques to be used in other areas is high and we have programmes with medical diagnostic companies designed to exploit these new markets.

 

Laser surgery is a fast growing area particularly for ophthalmological, prostate and aesthetic treatments and has been a key driver of 2015 growth. We believe there is further potential for both current and new areas of laser surgery.

 

G&H has an established sub-system and system presence with a number of our Life Sciences customers and we see further potential for moving up the value chain in this area during 2016.

 

Markets and Applications - Scientific Research 

 

For G&H the Scientific Research market is dominated by a small number of 'Big Science' projects in the fields of nuclear fusion research and synchrotron radiation sources. This is a prestigious and profitable sector for G&H, but we are not relying on this area for significant future growth. Revenue was marginally down year on year by £0.3m.

 

Operations

 

The planned closure of our Melbourne, Florida site was completed in December 2014, with the transfer of the business to our other acousto-optic sites in Palo Alto, California and Ilminster.

 

We expect the relocation of our site in Palo Alto to nearby Fremont to be complete in the calendar year 2015. This will provide us with an improved facility and extra space for expansion.

 

An upgrade of our Cleveland, Ohio site commenced in 2015 and we expect it to be substantially complete by the end of the calendar year 2016. This is a key site, where our crystal growth takes place and the improvements will ensure it meets our anticipated future requirements.

 

Investment in our Torquay site which provided both an upgrade to, and an expansion of, the facility was substantially completed in 2015.

 



 

 

 

Outlook

 

During 2015 Gooch & Housego has made good progress in executing on its strategic objectives, met management's expectations for revenue and profit growth and made a number of significant investments in line with our strategic vision for the business.

 

A good start has been made on the organisational changes required to make G&H a more unified global company and this process will continue into the next financial year.

 

The upgrading and expansion of key sites will continue in 2016. Our continued commitment to the principles of lean manufacturing will ensure they are further embedded in the business. This should result in an improved manufacturing performance.

 

Investment in A&D business development is starting to pay off and our intention is to make a similar investment in Life Sciences.

 

R&D spending has increased and a more focused use of G&H's resources should enable us to deliver our selected high return projects more efficiently to our customers over the next few years.

 

These strategic initiatives combined with a solid year end order book mean the Board remains confident that Gooch & Housego is well positioned to deliver further progress in 2016 and beyond.

 

 

 

 

 

 

Mark Webster

Chief Executive Officer



 

Performance Overview

 

The business has once again delivered double digit growth for both revenue and adjusted profit.

 

The Company has delivered an excellent cash performance in the year, increasing its net cash position from £8.7m at 30 September 2014 to £17.3m at 30 September 2015.  During 2015, Gooch & Housego invested £3.2m net in property, plant and equipment and intangible assets and continued to review certain acquisition opportunities.

REVENUE











2015


2014

Year ended 30 September

£'000

%


£'000

%

 

Industrial

46,054

59%


39,813

57%

 

Aerospace & Defence (A&D)

19,804

25%


18,786

27%

 

Life Sciences

8,978

11%


7,318

10%

 

Scientific Research

3,866

5%


4,139

6%

 

Group Revenue

78,702

100%


70,056

100%

 

 

Group revenue for the year was a record £78.7m.  This represents all organic growth and is an increase of £8.6m, or 12% over the previous year of £70.1m.  On a constant currency basis revenue was 8% higher than the previous year as a result of a generally beneficial foreign exchange environment.

 

 

In the financial year under review, adjusted operating margins were 16.6%, compared to 17.1% in 2014.  The deterioration to margin was a result of a lower than expected performance from the Instrumentation business and additional costs from the investment in R&D, the drive for lean manufacturing and investment in business development in Aerospace & Defence.

 

In our Industrial segment, revenue grew by 15.7% from £39.8m last year to £46.1m this year.  Revenue in our Aerospace & Defence business grew by 5.4%, from £18.8m to £19.8m, and similarly, our Life Sciences business grew from £7.3m to £9.0m, an increase of 22.7%. Sales into our smallest segment, Scientific Research, fell by 6.6%.

 

 

GROUP EARNINGS PERFORMANCE










All amounts in £'000

Adjusted


Reported

Year ended 30 September

2015

2014


2015

2014

 

Operating profit

13,102

11,974


10,294

8,395

 

Net finance costs

(188)

(514)


(188)

(514)

 

Profit before taxation

12,914

11,460


10,106

7,881

 

Taxation

(3,380)

(2,951)


(2,647)

(2,482)

 

Profit for the year

9,534

8,509


7,459

5,399

 

Basic earnings per share (p)

39.5p

35.6p


30.9p

22.5p

 



 

 

The Group adjusted profit before tax amounted to £12.9m (2014: £11.5m) and represented a return on revenue of 16.4% which is consistent with the previous year.  Statutory profit before tax was £10.1m compared with £7.9m last year, including the remaining one-off costs associated with the closure of our Melbourne facility and the Palo Alto facility move.

 

The adjusted effective rate of tax was 26.2% (2014: 25.8%). The effective rate of tax of 26.2% (2014: 31.5%) was lower due to the effect of non-taxable exceptional items and the write-off of deferred tax assets due to the closure of the Melbourne site in 2014.  The rate reflects a combination of the varying tax rates applicable throughout the countries in which the Group operates, principally the UK and the USA.  The effect of the reduction of the UK corporation tax rate was more than offset by a greater proportion of the Group's profit being taxed in the US.

 

The introduction of the patent box tax regime from April 2013 has not contributed to a lower tax rate in 2015 and will not in 2016 due to the Group historically filing patents in the USA rather than in the UK or Europe. Current policy is to file patents in the UK when possible. The effective rate of tax should benefit in the future from further reductions in the UK tax rate, although the increased percentage of profit generated in the USA, where tax rates are higher, will mitigate this benefit.

 

Adjusted earnings per share (EPS) increased from 35.6p to 39.5p.  Basic EPS was 30.9p compared with 22.5p last year.

 

RECONCILIATION OF ADJUSTED PERFORMANCE MEASURES

 


Operating Profit

Net finance costs

Taxation

Earnings

per share

Year ended 30 September

2015

£000

2014

£000

2015

£000

2014

£000

2015

£000

2014

£000

2015

pence

2014

pence

Reported

10,294

8,395

(188)

(514)

(2,647)

(2,482)

30.9p

22.5p

Amortisation of acquired intangible assets

1,604

1,525

-

-

(419)

(381)

4.9p

4.8p

Gain on bargain purchase

-

(1,039)

-

-

-

-

-

(4.3p)

Impairment of goodwill

-

1,538

-

-

-

-

-

6.4p

Restructuring costs

1,204

1,555

-

-

(314)

(88)

3.7p

6.2p

Adjusted

13,102

11,974

(188)

(514)

(3,380)

(2,951)

39.5p

35.6p

 

NON GAAP MEASURES

 

The Company uses a number of non GAAP measures which are shown in the table above and in the segmental analysis.  These measures are used to illustrate the impact of non-recurring and non-trading items on the Company's financial results.  These are the impact of the amortisation of acquired intangible assets and costs associated with restructuring activities and also include the gain on bargain purchase of Spanoptic and impairment of goodwill in 2014. The Company also uses the term EBITDA (Earnings before interest, taxation, depreciation and amortisation), which is a commonly used measure of operating performance and cash flow.

 



 

SEGMENTAL ANALYSIS

 

Industrial

 

Our Industrial business grew strongly during the year, with revenues of £46.1m, compared with £39.8m last year. Revenue from the Group's traditional Q-switch product increased marginally compared to 2014, although it continues to fall as a percentage of the business, as anticipated, and now represents 9.9% of total group revenue (2014: 10.2%). We believe this reflects the continuing shift towards the use of fibre lasers in materials processing applications.  Once again this appears to be supported by the significant increase in sales of fibre laser components experienced by Gooch & Housego in 2015.  Telecommunications revenues were up significantly in the year due to increased demand for our high reliability fibre components for under-sea telecommunications applications.

 

After adjusting for the Melbourne site restructuring costs and the costs associated with the Palo Alto facility move, operating profit for the Industrial sector as a whole was 18.9% higher at £9.6m, compared with £8.1m last year. This reflects a combination of the growth in our telecommunications business and operational gearing resulting from additional volume flowing through our Palo Alto facility.

 

Aerospace & Defence (A&D)

 

A&D revenue increased by 5.4% from £18.8m to £19.8m in 2015.  The business continues to provide both components and sub-systems to the Company's European and US A&D customers.  This business continues to represent a growth opportunity for Gooch & Housego, as optical technologies continue to be increasingly deployed in this market sector.  Operating margins in this sector fell as a result of investment in business development resources, some one-off revenue in 2014 not recurring in 2015 and tighter margins on our navigation components business.

 

Life Sciences

 

In 2015 Life Sciences revenue grew by over 22%.  Sales of electro-optic products into the laser surgery market and of fibre optic assemblies for Optical Coherence Tomography were both strong.  Adjusted operating profit in this sector was up by 57% as a result of this. We continue to believe this market offers a significant growth opportunity.

 

Scientific Research

 

Our activities in the Scientific Research market are dominated by a small number of large, long-term programmes.   This market was marginally weaker for Gooch & Housego in 2015 as a result of softness in the general research market. However, due to a product mix benefit, adjusted operating profit improved to £0.7m, compared to £0.4m in 2014.

 

RESEARCH & DEVELOPMENT (R&D)

 

Gooch & Housego continues to invest in R&D in all areas of the business and regards this as fundamental to the continued growth of the company.  There were eighteen product releases in 2015, together with two new patents granted.

 

Expenditure on R&D in the year to 30 September 2015 increased by 14.2% from £5.6m to £6.4m.  A proportion of this increase was funded through UK and European grant funding.  R&D expenditure represented 8.0% of revenue (2014: 8.1%).  The Group capitalised £0.7m (2014: £0.5m) of development expenditure.




 

 

SITE PERFORMANCE

 

The decision was made in 2014 to close the Melbourne, Florida, operation and to transfer the business to the Company's Ilminster, UK, and Palo Alto, California, facilities.  This process is now complete.  All product lines have been transferred, the site has been closed and the property sold.  The closure of the Melbourne site entailed a cash cost of $0.8 million and is expected to deliver annual cash savings of $1.0 million.

 

As reported at the half year, the Company is in the process of moving its Palo Alto site to nearby Fremont, which will provide improved facilities and room for further growth. This transfer was delayed and is now expected to be completed by the end of the calendar year.  This move has given rise to an exceptional cost of £0.8m in 2015.  It is expected that a further £0.2m will be incurred to finalise this move in the new financial year.

 

In addition to its two core strategies, in 2015 the business has identified three areas of focus as part of a performance improvement programme. These are: a) ensuring a consistent level of operational excellence across all sites, b) developing deeper ties with key target customers and c) ensuring we have a balanced R&D portfolio that meets the business's strategic goals. As part of this initiative, the Company has committed to upgrading its Cleveland, Ohio facility. This facility houses the business's world leading crystal growth capabilities, is a key contributor to current and future profitability and will benefit from some modernisation.  The refurbished facility will help drive much needed operational efficiency as well as showcasing our capabilities to customers.  The upgrade is expected to be a two-year programme costing in the region of $5m. 

 

RESTRUCTURING COSTS

Restructuring costs of £1.2m (2014: £1.6m) related to the Melbourne site closure (£0.4m) and the Palo Alto site move (£0.8m). The costs primarily include the write off of leasehold improvements, staff costs and legal expenses.



 

BALANCE SHEET

 

The Group's shareholders' funds at the end of the year were £78.4m, an increase of £8.4m over the prior year.  This increase comprised £0.2m due to the issue of share capital, £1.8m due to foreign exchange and £6.4m from retained earnings.

 

Additions to property, plant and equipment totalled £4.2m.  The main additions related to investment in plant and machinery and the expansion of our Torquay facility and the Palo Alto facility move.

 

Working capital was 20.8% of revenue in the current year compared to 22.0% in 2014. 

 

As part of the preparations for moving its Palo Alto site to nearby Fremont, the business has built inventory levels to satisfy expected customer requirements while the new facility is brought on line.  The planned inventory build, together with the impact of exchange rates and positive trading patterns, has resulted in inventory levels increasing by £1.4 million to £16.0 million since the previous year end.   Once the impact of currency and the inventory build are removed, the underlying inventory fell by £0.8m, or 5.6%, in the year.   

 

Trade and other receivables have increased by £1.4m from £13.0m in 2014 to £14.4m at this year-end.

 

Cash balances at 30 September 2015 were £22.6m, compared with £17.1m at 30 September 2014.  Net cash flows from operating activities generated £13.6m, compared with £13.7m last year. During the year the business moved from a net cash position of £8.7m as at 30 September 2014 to a net cash position of £17.3m.

 

MOVEMENT IN NET CASH

All amounts in £m

Gross

Cash

Gross

Debt

Net

Cash

At 1 October 2014

17.1

(8.4)

8.7

Operating cash flows

15.9

-

15.9

Debt repayment (net of drawdown)

(3.5)

3.5

-

Net capital expenditure

(3.2)

-

(3.2)

Working capital

(1.2)

-

(1.2)

Proceeds from share issue

0.1

-

0.1

Interest, tax and dividends

(3.1)

-

(3.1)

Exchange movement

0.5

(0.4)

0.1

At 30 September 2015

22.6

(5.3)

17.3

 

ORDER BOOK

 

As at 30 September 2015, the Group order book stood at £36.3m, compared to £32.8m at the end of the 2014 financial year, an 11% increase.  On a constant currency basis the order book was 6% higher.  Book to bill ratios for the business as a whole were 1.08 times (six month rolling average) as at 30 September 2015.

 

STAFF

 

The Group workforce increased from 664 at 30 September 2014 to 700 at the end of September 2015, an increase of 36. This is a net position and therefore reflects both the reductions in staffing resulting from the work the business has done in integration and rationalisation of sites and processes, temporary staff required to meet high peak demand at specific sites and the additional investment that the business has made in engineering, business development and management.

 

 

DIVIDENDS

 

The Directors propose a final dividend of 5.2p per share making a total dividend per share for the year of 8.2p (2014: 7.2p), an increase of 13.9%.  The final dividend, if approved, will be payable on 3 March 2016 to shareholders on the Company's share register as at the close of business on 18 December 2015.

 

KEY PERFORMANCE INDICATORS (KPIs)

 

The Group objective is to deliver sustainable, long-term growth in revenue and profits.  This is to be achieved through the execution of the Board's strategies.

 

In striving to achieve these strategic objectives, the main financial performance measures monitored by the Board are:

 

Total revenue growth

2015

2014

2013

At actual exchange rates

12%

11%

4%

At constant exchange rates

8%

16%

3%

 

The Board is focused on driving revenue growth by investing both organically and through acquisitions.  The Group business has delivered underlying growth, whilst experiencing variable demand patterns within its core markets.

 

Target market revenue

2015

2014

2013

Aerospace & Defence  (£m)

19.8

18.8

17.3

Life Sciences (£m)

9.0

7.3

7.4

 

The Group target markets of Aerospace & Defence and Life Sciences provide a route to sustainable growth, and a more diversified revenue base. These markets also provide significant opportunities for Gooch & Housego to migrate up the value-chain from materials and components to higher value sub-assemblies, modules and systems in response to the trend for our larger customers to outsource increasingly complex parts of their business.  The business has made good progress in addressing its target markets of Aerospace & Defence and Life Sciences which, in aggregate, have increased by 10.3% in the 2015 financial year.

 

Net cash analysis

2015

2014

2013

Net cash (£m)

17.3

8.7

5.7

 

In order to balance business risk with the investment needs of the Company, management closely monitors and manages net cash.  This year the business increased its net cash position from £8.7m to £17.3m, putting the business in a strong position both in terms of headroom for further investment and from the perspective of managing its business risk.

 

Earnings per share (EPS)

2015

2014

2013

38.9p

35.2p

30.5p

 

As a result of a strong trading performance, the business has been able to deliver growth in adjusted diluted EPS of 10.5%, from 35.2p to 38.9p in 2015.

 

The revenue, cash and earnings per share targets for the year were met.



 

Group Income Statement

For the year ended 30 September 2015 (unaudited)

 



2015

2014


Note

£000

£000

Revenue

2

78,702

70,056

Cost of revenue


(47,659)

(41,706)

Gross profit


31,043

28,350

Research and Development


(5,712)

(5,160)

Sales and Marketing


(5,626)

(4,498)

Administration


(10,353)

(10,026)

Other income and expenses


942

(271)

Operating profit

2

10,294

8,395

Finance income


26

8

Finance costs


(214)

(522)

Profit before income tax expense


10,106

7,881

Income tax expense

3

(2,647)

(2,482)

Profit for the year


7,459

5,399





Basic earnings per share

 

4

30.9p

22.5p

Diluted earnings per share

4

30.4p

22.3p

 

 

 

Reconciliation of operating profit to adjusted operating profit:

 



2015

2014



£000

£000

Operating profit


10,294

8,395

Amortisation of acquired intangible assets


1,604

1,525

Restructuring costs


1,204

1,555

Gain on bargain purchase of Spanoptic Limited


-

(1,039)

Impairment of goodwill


-

1,538

Adjusted operating profit


13,102

11,974

                                                               

 

 


                                                               

Group Balance Sheet

For the year ended 30 September 2015 (unaudited)

 



2015

2014



£000

£000

Non-current assets




Property, plant and equipment


24,915

24,140

Intangible assets


20,155

20,668

Deferred income tax assets

          

2,552

3,114



47,622

47,922

Current assets




Inventories


16,013

14,663

Income tax assets


854

487

Trade and other receivables


14,394

13,005

Cash and cash equivalents


22,556

17,094



53,817

45,249

Current liabilities




Trade and other payables


(14,059)

(11,829)

Borrowings


(39)

(8,048)

Income tax liabilities


(411)

(244)

Provision for other liabilities and charges


(342)

(447)



(14,851)

(20,568)




24,014

Net current assets


38,966

24,681





Non-current liabilities




Borrowings


(5,189)

(360)

Deferred income tax liabilities


(3,032)

(2,306)



(8,221)

(2,666)





Net assets


78,367

69,937





Shareholders' equity

Capital and reserves
attributable to equity shareholders




Called up share capital


4,818

4,774

Share premium account


15,530

15,420

Merger reserve


2,671

2,671

Hedging reserve


-

(21)

Cumulative translation reserve


1,030

(770)

Retained earnings


54,318

47,863

Total equity


78,367

69,937



 


Group Statement of Changes in Shareholders' Equity

For the year ended 30 September 2015 (unaudited)

 

 


 

 

 

Note

Called up share
capital

£000

Share
premium
account
£000


Merger
reserve
£000

 

Hedging

reserve
£000

 

Retained

earnings
£000

 

Total

equity

£000

 

At 1 October 2013


4,620

15,213

2,671

(79)

42,514

64,939

Profit for the financial year


-

-

-

-

5,399

5,399

Other comprehensive income for the year


-

-

-

58

90

148

Total comprehensive income for the year


-

-

-

58

5,489

5,547

Dividends

5

-

-

-

-

(1,569)

(1,569)

Proceeds from shares issued


154

207

-

-

(149)

212

Fair value of employee services


-

-

-

-

361

361

Tax credit relating to share option schemes


-

-

-

-

447

447

Total contributions by and distributions to owners of the parent recognised directly in equity


154

207

-

-

(910)

(549)

At 30 September 2014


4,774

15,420

2,671

(21)

47,093

69,937

At 1 October 2014


4,774

15,420

2,671

(21)

47,093

69,937

Profit for the financial year


-

-

-

-

7,459

7,459

Other comprehensive income for the year


-

-

-

21

1,800

1,821

Total comprehensive income for the year


-

-

-

21

9,259

9,280

Dividends

5

-

-

-

-

(1,823)

(1,823)

Proceeds from shares issued


44

110

-

-

(38)

116

Fair value of employee services


-

-

-

-

485

485

Tax credit relating to share option schemes


-

-

-

-

372

372

Total contributions by and distributions to owners of the parent recognised directly in equity


44

110

-

-

(1,004)

(850)

At 30 September 2015


4,818

15,530

2,671

-

55,348

78,367

 

 

 

 

 

 

 



 

 

Group Statement of Comprehensive Income

For the year ended 30 September 2015 (unaudited)



2015

2014



£000

£000





Profit for the year


7,459

5,399





Other comprehensive income - items that may be reclassified subsequently to profit or loss




Fair value adjustment of interest rate swap net of tax


21

58

Currency translation differences


1,800

90

Other comprehensive income for the year net of tax


1,821

148





Total comprehensive income for the year attributable to the shareholders of Gooch & Housego PLC


9,280

5,547









 



 

 

 

 

 

Group Cash Flow Statement

For the year ended 30 September 2015 (unaudited)

 



2015

2014


Note

£000

£000

Cash flows from operating activities




Cash generated from operations

6

14,692

15,298

Income tax paid


(1,067)

(1,625)

Net cash generated from operating activities


13,625

13,673





Cash flows from investing activities




Acquisition of subsidiaries, net of cash acquired


-

(5,532)

Purchase of property, plant and equipment


(3,053)

(1,909)

Sale of property, plant and equipment


635

26

Purchase of intangible assets


(793)

(852)

Interest received


26

8

Net cash used in investing activities


(3,185)

(8,259)





Cash flows from financing activities




Drawdown of borrowings


5,168

4,832

Repayment of borrowings


(8,777)

(3,196)

Proceeds from issues of share capital


115

105

Dividends paid to ordinary shareholders


(1,823)

(1,569)

Interest paid


(189)

(569)

Net cash used in financing activities


(5,506)

(397)





Net increase in cash and cash equivalents


4,934

5,017

Cash and cash equivalents at beginning of the year


17,094

12,088

 

Exchange gains / (losses) on cash


528

(11)

Cash and cash equivalents at the end of the year


22,556

17,094

 

Analysis of net cash


At 1 Oct 2014

 

Cash flow

Exchange movement

Non cash movement

At 30 Sep

2015


£000

£000 

£000  

£000

£000

Cash at bank and in hand

17,094

4,934 

528  

-

22,556

Debt due within 1 year

(7,992)

8,720 

(728)  

-

-

Debt due after 1 year

(320)

(5,168) 

299  

-

(5,189)

Finance leases

(96)

57 

-  

-

(39)

Net cash

8,686

8,543 

99  

-

17,328



 

Notes to the preliminary report

 

1.         Basis of preparation

 

The unaudited Preliminary Report has been prepared under the historical cost convention and in accordance with International Financial Reporting Standards ("IFRS") as adopted by the European Union and interpretations in issue at 30 September 2015.  

 

The Preliminary Report does not constitute statutory financial statements within the meaning of section 434 of the Companies Act 2006 and has not been audited.  

 

Comparative figures in the Preliminary Report for the year ended 30 September 2014 have been taken from the Group's audited statutory financial statements on which the Group's auditors, PricewaterhouseCoopers LLP, expressed an unqualified opinion.

 

The accounting policies adopted are consistent with those of the annual financial statements for the year ended 30 September 2014, as described in those financial statements. New standards or interpretations which came into effect for the current reporting period did not have a material impact on the net assets or results of the Group.

 

The Preliminary Report will be announced to all shareholders on the London Stock Exchange and published on the Group's website on 1 December 2015. Copies will be available to members of the public upon application to the Company Secretary at Dowlish Ford, Ilminster, Somerset, TA19 0PF.

 

 

2.             Segmental analysis

 

The Company's segmental reporting reflects the information that management uses within the business.  The business is divided into four market sectors, being Aerospace & Defence, Life Sciences, Industrial and Scientific Research, together with the Corporate cost centre.

 

The industrial business segment primarily comprises the industrial laser market for use in the semiconductor and microelectronic industries, but also includes other industrial applications such as metrology and telecommunications.  Scientific Research covers academic and government funded research including major multi-national projects.

 

 


Aerospace & Defence

Life Sciences

Industrial

Scientific Research

Corporate

Total


£000

£000

£000

£000

£000

£000

For year ended 30 September 2015







Revenue







Total revenue

19,880

8,978

51,892

3,866

-

84,616

Inter and intra-division

(76)

-

(5,838)

-

-

(5,914)

External revenue

19,804

8,978

46,054

3,866

-

78,702

Divisional expenses

(17,112)

(7,067)

(35,885)

(3,058)

(783)

(63,905)

EBITDA¹

2,692

1,911

10,169

808

(783)

14,797

EBITDA %

13.6%

21.3%

22.1%

20.9%

-

18.8%

Depreciation and amortisation

(572)

(322)

(1,746)

(129)

(130)

(2,899)

Operating profit before amortisation of acquired intangible assets

2,120

1,589

8,423

679

(913)

11,898

Amortisation of acquired intangible assets

-

-

-

-

(1,604)

(1,604)

Operating profit

2,120

1,589

8,423

679

(2,517)

10,294

Operating profit margin %

10.7%

17.7%

18.3%

17.6%

-

13.1%

Add back restructuring costs

20

23

1,156

5

-

1,204

Operating profit excluding restructuring costs

2,140

1,612

9,579

684

(2,517)

11,498

Adjusted profit margin %

10.8%

18.0%

20.8%

17.7%

-

14.6%

Finance costs

-

-

-

-

(188)

(188)

Profit before income tax expense

2,120

1,589

8,423

679

(2,705)

10,106

 

¹EBITDA = Earnings before interest, tax, depreciation and amortisation

 

Management have added back the restructuring costs in the above analysis. This has been shown because the Directors consider the analysis to be more meaningful excluding the impact of this non-recurring expense.



 

2.         Segmental analysis (continued)

 

 


Aerospace & Defence

Life Sciences

Industrial

Scientific Research

Corporate

Total


£000

£000

£000

£000

£000

£000

For year ended 30 September 2014







Revenue







Total revenue

18,786

7,318

44,248

4,139

-

74,491

Inter and intra-division

-

-

(4,435)

-

-

(4,435)

External revenue

18,786

7,318

39,813

4,139

-

70,056

Divisional expenses

(15,612)

(6,083)

(31,207)

(3,713)

(214)

(56,829)

EBITDA¹

3,174

1,235

8,606

426

(214)

13,227

EBITDA %

16.9%

16.9%

21.6%

10.3%

-

18.9%

Depreciation and amortisation

(522)

(270)

(1,702)

(152)

(162)

(2,808)

Operating profit before amortisation of acquired intangible assets

2,652

965

6,904

274

(376)

10,419

Amortisation of acquired intangible assets, gain on bargain purchase and impairment of goodwill

-

-

-

-

(2,024)

(2,024)

Operating profit

2,652

965

6,904

274

(2,400)

8,395

Operating profit margin %

14.1%

13.2%

17.3%

6.6%

-

12.0%

Add back Melbourne closure costs

79

59

1,155

91

-

1,384

Operating profit excluding Melbourne closure costs

2,731

1,024

8,059

365

(2,400)

9,779

Adjusted profit margin %

14.5%

14.0%

20.2%

8.8%

-

14.0%

Finance costs

-

-

-

-

-

(514)

Profit before income tax expense

2,652

965

6,904

274

(2,914)

7,881

 

 

Management have added back the cost of the Melbourne site closure in the above analysis. This has been shown because the Directors consider the analysis to be more meaningful excluding the impact of this non-recurring expense.

 

All of the amounts recorded are in respect of continuing operations.

 

Analysis of net assets / (liabilities) by location:

 


2015

2015

2015

2014

2014

2014


Assets

Liabilities

Net Assets

Assets

Liabilities

Net Assets


£000

£000

£000

£000

£000

£000

United Kingdom

49,345

(7,754)  

41,591   

38,387    

(12,388)    

25,999

USA

51,207

(14,924)  

36,283   

54,282    

(10,345)    

43,937

Continental Europe

872

(389)  

483   

486    

(497)    

(11)

Asia Pacific

15

(5)  

10   

16    

(4)    

12


101,439

(23,072)  

78,367   

93,171    

(23,234)    

69,937

 

 

2.         Segmental analysis (continued)

 

Analysis of revenue by destination:




2015

£000

2014

£000

United Kingdom



14,897

14,412

USA



34,762

29,657

Continental Europe



16,890

14,425

Asia Pacific and Other



12,153

11,562

Total revenue



78,702

70,056

 

 

3.             Income tax expense

 

Analysis of tax charge in the year




2015
£000

2014
£000

Current taxation




UK Corporation tax


1,480

1,446

Overseas tax


724

630

Adjustments in respect of prior year tax charge


(983)

(165)

Total current tax


1,221

1,911





Deferred tax




Origination and reversal of temporary differences


274

49

Adjustments in respect of prior year deferred tax


1,152

504

Impact of UK tax rate change to 20% (2014: 20%)


-

18

Total deferred tax


1,426

571





Income tax expense per income statement


2,647

2,482





 



 

 

4.             Earnings per share

 

The calculation of earnings per 20p Ordinary Share is based on the profit for the year using as a divisor the weighted average number of Ordinary Shares in issue during the year.  The weighted average number of shares for the year ended 30 September is given below:


2015

2014

Number of shares used for basic earnings per share

24,115,878

23,984,536

Dilutive shares

405,311

213,581

Number of shares used for dilutive earnings per share

24,521,189

24,198,117

 

 

A reconciliation of the earnings used in the earnings per share calculation is set out below:


2015

2014


£000

pence

per share

£000

pence

 per share

Basic earnings per share

7,459

30.9p

5,399

22.5p

Amortisation of acquired intangible assets (net of tax)

1,184

4.9p

1,144

4.8p

Goodwill impairment

-

-

1,538

6.4p

Gain on bargain purchase

-

-

(1,039)

(4.3p)

Restructuring costs (net of tax)

891

3.7p

1,467

6.2p

Total adjustments net of income tax expense

2,075

8.6p

3,110

13.1p

Adjusted basic earnings per share

9,534

39.5p

8,509

35.6p






Basic diluted earnings per share

7,459

30.4p

5,399

22.3p

Adjusted diluted earnings per share

9,534

38.9p

8,509

35.2p

 

 

Basic and diluted earnings per share before amortisation and other adjustments has been shown because, in the opinion of the Directors, it provides a useful measure of the trading performance of the Group.

 



 

5.             Dividends

 

 



2015
£000

2014
£000

Final 2014 dividend paid in 2015: 4.6p per share (Final 2013 dividend paid in 2014: 4.0p per share)


1,101

950

2015 Interim dividend paid: 3.0p per share (2014: 2.6p)


722

619



1,823

1,569

The Directors propose a final dividend of 5.2p per share making the total dividend paid and proposed in respect of the 2015 financial year 8.2p (2014: 7.2p). 

 

 

 

6.             Cash generated from operating activities







2015

£000

2014

£000

Profit before income tax


10,106

7,881

Adjustments for:




- Amortisation of acquired intangible assets


1,604

1,525

- Amortisation of other intangible assets


301

164

- Gain on bargain purchase of Spanoptic Limited


-

(1,039)

- Impairment of goodwill


-

1,538

- Depreciation


2,715

2,644

- Loss on disposal of property, plant and equipment


508

21

- Share based payment obligations


485

361

- Finance income


(26)

(8)

- Finance costs


214

522

Total


5,801

5,728

Changes in working capital




- Inventories


(729)

(538)

- Trade and other receivables


(1,101)

2,097

- Trade and other payables


615

130

Total


(1,215)

1,689





Cash generated from operating activities


14,692

15,298

 

 

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
FR WGGQGGUPAGMU
UK 100

Latest directors dealings